Moleculin Biotech, Inc. (MBRX) financial statements (2021 and earlier)

Company profile

Business Address 5300 MEMORIAL DRIVE
HOUSTON, TX 77007
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1511785
Cash and cash equivalents1511785
Receivables00   
Prepaid expense13110
Other undisclosed current assets1(0)   
Total current assets:1713885
Noncurrent Assets
Operating lease, right-of-use asset00
Property, plant and equipment00000
Intangible assets, net (including goodwill), including:1111111111
Intangible assets, net (excluding goodwill)11    
Other undisclosed intangible assets, net (including goodwill)011111111
Total noncurrent assets:1212121111
TOTAL ASSETS:2925201916
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:34421
Accounts payable1211 
Accrued liabilities2121 
Interest and dividends payable    0
Other undisclosed accounts payable and accrued liabilities    1
Debt    0
Deferred compensation liability  0  
Derivative instruments and hedges, liabilities  01 
Total current liabilities:34421
Noncurrent Liabilities
Long-term debt and lease obligation00   
Operating lease, liability00
Liabilities, other than long-term debt86100
Deferred compensation liability, classified   00
Deferred rent credit  0
Derivative instruments and hedges, liabilities861  
Total noncurrent liabilities:86100
Total liabilities:1110521
Stockholders' equity
Stockholders' equity attributable to parent, including:1816141715
Common stock00000
Common stock, share subscribed but unissued, subscriptions receivable(0)    
Additional paid in capital7555413220
Accumulated deficit(57)(40)(26)(14)(5)
Other undisclosed stockholders' equity attributable to parent000  
Total stockholders' equity:1816141715
TOTAL LIABILITIES AND EQUITY:2925201916

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Gross profit:   0 
Operating expenses(20)(18)(15)(9)(4)
Other undisclosed operating loss   (0) 
Operating loss:(20)(18)(15)(9)(4)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
00(0)  
Interest and debt expense    (0)
Loss from continuing operations before equity method investments, income taxes:(20)(18)(15)(9)(4)
Other undisclosed income from continuing operations before income taxes2    
Loss from continuing operations before income taxes:(17)(18)(15)(9)(4)
Income tax benefit 0   
Net loss:(17)(17)(15)(9)(4)
Other undisclosed net income (loss) attributable to parent 43(1) 
Net loss available to common stockholders, diluted:(17)(13)(12)(10)(4)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(17)(17)(15)(9)(4)
Comprehensive loss:(17)(17)(15)(9)(4)
Other undisclosed comprehensive income, net of tax, attributable to parent043  
Comprehensive loss, net of tax, attributable to parent:(17)(13)(12)(9)(4)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: